IBM unveils RFID system for secure prescriptions
IBM has unveiled a radio frequency identification (RFID) system for the tracking and tracing of pharmaceuticals.
IBM has unveiled a radio frequency identification (RFID) system for the tracking and tracing of pharmaceuticals.
It is estimated that one in 12 of the world’s prescriptions distributed each year contain counterfeit medicines. The US Food and Drug Administration has cited RFID as the most promising technology to help prevent such distributions.



The latest developments and trends in SDN
Join us as we sit down with a number of senior IT managers from multi-national enterprises to discuss the latest trends in the world of software-defined networks.
By submitting your personal information, you agree that TechTarget and its partners may contact you regarding relevant content, products and special offers.
You also agree that your personal information may be transferred and processed in the United States, and that you have read and agree to the Terms of Use and the Privacy Policy.
With the RFID system, RFID tags are embedded on products at the unit, case and pallet level, authenticating the product from manufacturer to wholesalers to hospitals and pharmacies.
Each tag contains a unique identifier – like a licence plate – that can be linked back to descriptive product information such as dosage and strength, lot number, manufacturer and expiration date.
The IBM RFID system for pharmaceutical tracking and tracing is based on the IBM WebSphere web services software platform, and on an architecture that allows customers to reuse existing assets – enabling them to build new applications quickly and at a lower cost for development.
Vote for your IT greats
Who have been the most influential people in IT in the past 40 years? The greatest organisations? The best hardware and software technologies? As part of Computer Weekly’s 40th anniversary celebrations, we are asking our readers who and what has really made a difference?
Vote now at: www.computerweekly.com/ITgreats
Start the conversation
0 comments